GlassScriptPhysician profile
Lisa M Cunningham
NPI 1265491898
$5,739.74
in general payments reported to CMS, 2019-2025
22 companies · $3,375 in 2025
The $3,375 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $260 · 2022: $356 · 2023: $983 · 2024: $766 · 2025: $3,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,005 · Consulting Fee: $1,000 · Travel and Lodging: $873 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,005.49 |
| Consulting Fee | $1,000.00 |
| Travel and Lodging | $873.31 |
| Education | $245.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,986.62 | 2021-2025 | Erleada |
| Medtronic, INC. | $988.53 | 2023-2025 | Interstim, Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $606.86 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $603.34 | 2021-2025 | Xtandi, Myrbetriq |
| Pfizer INC. | $330.15 | 2023-2025 | |
| Coloplast Corp | $136.12 | 2024 | |
| Janssen Scientific Affairs, LLC | $128.05 | 2022-2025 | Pipeline, Erleada |
| Boston Scientific Corporation | $127.35 | 2023-2025 | General - Pain Management, Varithena Administration Pack |
| Amgen INC. | $109.64 | 2024 | Evenity |
| Ferring Pharmaceuticals INC. | $108.21 | 2024-2025 | Adstiladrin |
| Telix Pharmaceuticals | $102.81 | 2025 | Illuccix |
| Astrazeneca Pharmaceuticals LP | $84.88 | 2024-2025 | Bevespi Aerosphere |
| Inari Medical, INC. | $81.75 | 2021 | |
| Novartis Pharmaceuticals Corporation | $79.35 | 2023-2024 | |
| Procept Biorobotics Corporation | $71.43 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $58.12 | 2025 | |
| Abbvie INC. | $48.02 | 2025 | |
| Dendreon Pharmaceuticals LLC | $23.73 | 2025 | Provenge |
| Sumitomo Pharma America, INC. | $19.80 | 2024 | Orgovyx |
| Blue Earth Diagnostics | $17.04 | 2023 | |
| Tolmar, INC. | $14.40 | 2023 | |
| Antares Pharma, INC. | $13.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.